AG-HYDROXYCHLOROQUINE DIN 02510863
Health Canada record
| Active ingredient(s) | HYDROXYCHLOROQUINE SULFATE 200 MG |
|---|---|
| Dosage form | Tablet |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | P01BA02 HYDROXYCHLOROQUINE |
| Original market date | |
| Current status date | 19-Jan-2021 |
| Source | Health Canada DPD |
Establishment licence of the holder
Angita Pharma Inc. — licence 101870, currently licensed, last inspection rating C (2025-01-13).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing HYDROXYCHLOROQUINE SULFATE
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02506696 | ACH-HYDROXYCHLOROQUINE SULFATE | ACCORD HEALTHCARE INC | Tablet | HYDROXYCHLOROQUINE SULFATE 200 MG | Approved |
| 02246691 | APO-HYDROXYQUINE | APOTEX INC | Tablet | HYDROXYCHLOROQUINE SULFATE 200 MG | Marketed |
| 02519348 | HYDROXYCHLOROQUINE | SANIS HEALTH INC | Tablet | HYDROXYCHLOROQUINE SULFATE 200 MG | Marketed |
| 02491427 | JAMP HYDROXYCHLOROQUINE SULFATE | JAMP PHARMA CORPORATION | Tablet | HYDROXYCHLOROQUINE SULFATE 200 MG | Marketed |
| 02424991 | MINT-HYDROXYCHLOROQUINE | MINT PHARMACEUTICALS INC | Tablet | HYDROXYCHLOROQUINE SULFATE 200 MG | Marketed |
| 02511886 | NRA-HYDROXYCHLOROQUINE | NORA PHARMA INC | Tablet | HYDROXYCHLOROQUINE SULFATE 200 MG | Marketed |
| 02017709 | PLAQUENIL | SANOFI-AVENTIS CANADA INC | Tablet | HYDROXYCHLOROQUINE SULFATE 200 MG | Marketed |
| 02252600 | MYLAN-HYDROXYCHLOROQUINE | MYLAN PHARMACEUTICALS ULC | Tablet | HYDROXYCHLOROQUINE SULFATE 200 MG | Cancelled Post Market |
| 02335816 | NU-HYDROXYQUINE | NU-PHARM INC | Tablet | HYDROXYCHLOROQUINE SULFATE 200 MG | Cancelled (Unreturned Annual) |
| 02247113 | PMS-HYDROXYCHLOROQUINE | PHARMASCIENCE INC | Tablet | HYDROXYCHLOROQUINE SULFATE 200 MG | Cancelled Pre Market |
| 02311011 | PRO-HYDROXYQUINE - 200 | PRO DOC LIMITEE | Tablet | HYDROXYCHLOROQUINE SULFATE 200 MG | Cancelled Post Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 25038 | 2021-01-19 | Abbreviated New Drug Submission (ANDS) | LICENSING AGREEMENT BETWEEN TWO COMPANIES |
International API supply for HYDROXYCHLOROQUINE SULFATE
13 valid EDQM Certificates of Suitability from 13 holders. 16 active FDA Drug Master Files.
Request a quote for AG-HYDROXYCHLOROQUINE